-
NEJM: Mycophenolate mofetil can be used as first-line treatment for patients with immune thrombocytopenia
Time of Update: 2021-09-11
Adding mycophenolate mofetil to glucocorticoids for first-line treatment of immune thrombocytopenia can achieve greater therapeutic response and reduce the risk of refractory or recurrent immune thrombocytopenia, but quality of life Decline .
-
Blood: A new model for predicting the long-term survival and prognosis of elderly AML patients receiving intensive chemotherapy!
Time of Update: 2021-09-04
Central point | Mutations in 7 genes can independently predict the overall survival of AML patients in different cytogenetic groups who are ≥60 years of age and receive intensive treatment .
-
Blood: Practical application of thrombopoietin receptor agonists in elderly patients with ITP
Time of Update: 2021-09-04
. TRA reactivity and dressing change, thrombosis /bleeding risk, and sustained remission (SROT) after stopping treatment were evaluated in 384 ITP patients 60 years and older.
-
Blood Cancer J: High-dose methotrexate can effectively prevent isolated CNS recurrence in DLBCL patients
Time of Update: 2021-09-03
Preventive HDMTX can reduce the recurrence rate of isolated CNS but does not reduce the CNS-systemic recurrence rate, systemic recurrence rate, and it does not improve the patient's survival prognosis .
-
Int J Cancer: Polyprezinc can effectively prevent chemotherapy-related oral mucositis in patients receiving hematopoietic stem cell transplantation
Time of Update: 2021-09-03
, Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi-institutional randomized controlled trial .
Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi-institutional randomized controlled trial in this message
-
Blood Cancer J: Obituzumab + Atezolizumab + Lenalidomide can effectively treat relapsed/refractory follicular lymphoma!
Time of Update: 2021-09-03
Recently, an open-label, multi-center phase Ib/II study published in the " Blood Cancer Journal " evaluated orbituzumab-atezolizumab-lenalidomide (G-atezo- len) The efficacy and safety of the triple regimen in the treatment of patients with relapsed/refractory (R/R) follicular lymphoma .
-
Br J Cancer: Delayed diagnosis of lymphoma patients is related to potential comorbidities
Time of Update: 2021-08-27
Therefore, in this study, the researchers aimed to assess the association between comorbidities and delay in diagnosis in DLBCL or FL patients in the UK during the period 2005-2013 .
-
J Clin Oncol: Ixazomib + subcutaneous injection of rituximab + dexamethasone can effectively treat relapsed or refractory macroglobulinemia!
Time of Update: 2021-08-26
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study .
00105Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I / II HOVON124 / ECWM-R2 Study in this message
-
Ferritin may become a marker for the diagnosis, differential diagnosis and prognosis of IrAEs
Time of Update: 2021-08-26
When adverse events occurred in the irAE group, the ferritin content (normal range 35-150μg/L) rose from the baseline value of 86μg/L to the median value of 927μg/L .
Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events.
-
CJASN: Roxastat can effectively correct anemia in non-dialysis-dependent CKD patients without increasing the risk of cardiovascular events
Time of Update: 2021-08-26
Roxastat can effectively increase the hemoglobin level of non-dialysis-dependent CKD patients, correct anemia, and reduce the need for blood transfusion without increasing the risk of MACE .
-
Clin Cancer Res: 9-year follow-up results for patients with follicular lymphoma after receiving alloSCT or autoSCT
Time of Update: 2021-08-26
In short, the study showed that compared with autoSCT, alloSCT is curative and can provide a higher survival rate for patients with recurrent follicular lymphoma .
For patients with recurrent follicular lymphoma, compared with autoSCT, alloSCT is curative and can provide a higher survival rate.
-
J Clin Oncol: Venetoclax+Darelimumab+Dexamethasone±Bortezomib can effectively treat relapsed/refractory multiple myeloma!
Time of Update: 2021-08-26
11) Venetoclax (Wei Naituo G) is an oral BCL-2 inhibitor with single-agent activity for patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocationThis phase 1 study (NCT03314181) evaluated the use of venetork combined with daratumumab and dexamethasone (VenDd) in RRMM patients with t(11;14) translocation, and VenDd+bortezomib (VenDVd) in The efficacy of cytogenetic unselected RRMM patients .
-
Blood: Bentuximab combined with nivolumab to rescue the long-term prognosis of relapsed/refractory Hodgkin's lymphoma
Time of Update: 2021-08-26
The long-term follow-up of BV and Nivo as the primary rescue plan showed long-lasting efficacy and excellent progression-free survival (PFS), especially in patients who underwent transplantation directly after the end of the study treatment, and there was no additional toxicity.
-
Allogene's universal BCMA CAR-T cells obtained the U.S. FDA fast-track designation medical Maimeng broke the news
Time of Update: 2021-08-22
Recommended reading: ASCO 2021: Allogene announces the latest clinical data of two allogeneic CD19 CAR-T drug treatments Yimai Meng broke the news that BCMA: MM's popular target Multiple myeloma (MM) is a clonal plasma cell abnormality The proliferative malignant disease is also the second most common hematological malignancy after non-Hodgkin’s lymphoma.
-
Professor Nicolaus Kröger, Chairman of EBMT: GVHD prevention is very important, and ATG has a bright future in clinical application
Time of Update: 2021-08-22
In the prevention and management of GVHD after hematopoietic stem cell transplantation for hematological malignancies, in the latest version of the EBMT consensus recommendation in 2020, calcineurin inhibitor (NCI) tacrolimus (TAC) ) And cyclosporine A (CsA) can be used for GVHD prevention in sibling/HLA unrelated donor (MUD) transplantation .
-
Allogeneic "stealth" CD19 CAR-T cell drug completes Phase 1 trial, the first patient to be administered medicine, Mai Meng broke the news
Time of Update: 2021-08-20
Click on the picture and register now July 3, 2021 /MedClub News/--On July 1, 2021, Precision BioSciences, a clinical-stage biotechnology company, announced today that the company's drug PBCAR19B phase 1 clinical trial has completed its first patient administration .
-
Express Organic Arsenic Anticancer Therapy Submits a New Drug Application in Japan to Treat Lymphoma
Time of Update: 2021-08-20
▎The content team editor of WuXi AppTec On June 30, 2021, Solasia Pharma of Japan announced that it has submitted a new drug application (NDA) for its research drug darinaparsin to the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of relapsed/refractory Peripheral T-cell lymphoma (PTCL) .
-
2021 ICML A+AVD program for the treatment of adolescents and young adults cHL
Time of Update: 2021-08-20
The 5-year follow-up results of the Phase III ECHELON-1 study showed that it is compatible with doxorubicin, bleomycin, and Changchun Compared with the base and dacarbazine (ABVD) regimen, the BV combined with doxorubicin, vinblastine and dacarbazine (A+AVD) regimen significantly improved the patient’s progression-free survival (PFS; HR: 0.
-
[One picture, one drug] Hengrui's new class 1 drug, Hytrobopar ethanolamine tablets, was approved for marketing
Time of Update: 2021-08-20
Adult patients with immunosuppressive disease (immunethrombocytopenia, ITP), and adult patients with severe aplastic anemia (SAA) who have poor efficacy on immunosuppressive therapy .
3% of patients in the HETROM-5 group reached the primary endpoint (odds ratio [OR] 32.
-
2021 ICML indolent non-Hodgkin's lymphoma treatment options
Time of Update: 2021-08-19
Abstract 79: Efficacy and safety of rituximab maintenance therapy in patients with MALT lymphoma: Phase II IELSG38 study results 1 research background IELSG19 study results show that compared with other single-agent regimens, rituximab combined with benzene The first-line treatment of chlorambucil in MALT lymphoma can significantly improve event-free survival (EFS) and progression-free survival (PFS) .
